What type of study is this?

This is a RCT study (also classified as: Phase 2).

September 10, 2025Clinical ophthalmologyOpen Access

Maximum Tolerated Medical Therapy for Glaucoma: Fixed-Dose Combinations of Timolol, Dorzolamide, Brimonidine with Latanoprost Versus Timolol, Dorzolamide with Latanoprost

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial compares IOP reduction using TDB-L and TD-L in patients with uncontrolled glaucoma, suggesting effective management options.

Both treatment groups achieved significant reductions in intraocular pressure (IOP) after 60 days.
TDB-L reduced IOP by 6.3 mmHg compared to 4.5 mmHg in the TD-L group, with a p-value of 0.042.
The study utilized a randomized, double-masked Phase IV trial design to assess the effectiveness and tolerability.
Highlighting the importance of maximizing treatment options, adding a fourth agent may enhance glaucoma management.

Olvera‐Montaño et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial compares IOP reduction using TDB-L and TD-L in patients with uncontrolled glaucoma, suggesting effective management options.